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REVIEW
Abstract: Adverse drug reactions (ADRs) are a significant cause of morbidity and mortality
and contribute to the incidence of adverse events, resulting in increased healthcare costs.
Healthcare providers need to understand their role and responsibility in the detection,
management, documentation, and reporting of ADRs, all essential activities for optimizing
patient safety. The purpose of this article is to summarize findings from important ADR
literature reviews and describe the components, and extent of participation, of the national
ADR reporting program available in New Zealand. A series of recommendations to increase
the detection of ADRs is also described.
Keywords: adverse drug reactions, post-marketing surveillance, pharmacists
Introduction
International attention to patient safety has been growing significantly since the
publication of the US Institute of Medicine (IOM) report “To err is human: building
a safer health system” (Kohn et al 1999). Similarly in New Zealand, the release of
Professor Peter Davis’s report on adverse events in New Zealand public hospitals in
December 2001 (Davis et al 2001) led to an increased awareness of various issues
related to patient safety, which have been further highlighted in more recent reports
in the local literature (Davis et al 2002, 2003; Morton and MacMillan 2003; Briant
et al 2004).
Adverse drug reactions (ADRs) are a significant cause of morbidity and mortality
and contribute to the incidence of adverse events, resulting in increased healthcare
costs (Lazarou et al 1998; Dormann et al 2000). Therefore, it is important to motivate
healthcare providers to understand their role and responsibility in the detection,
management, documentation, and reporting of ADRs, all essential activities for
optimizing patient safety.
The purpose of this article is to summarize findings from important ADR literature
reviews and to describe the components of the national ADR reporting program
available in New Zealand and the extent of participation of health professionals in
this program, particularly pharmacists. Finally, a series of recommendations to
increase the detection of ADRs is analyzed as a means to improve patient safety
through the promotion of a more active role on the part of the pharmacy professional.
Literature review
Adverse reactions are a recognized hazard of drug therapy. Although some ADRs
are minor and resolve without sequelae, others can cause permanent disability or
death. Many studies have assessed the incidence of ADRs in numerous settings, but
these estimates vary considerably. This may be due to known underreporting of ADRs
and differences in study methodology, populations studied, and ADR definitions.
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Various definitions of an ADR have been used around
the world. In New Zealand, as in many other countries, the
World Health Organization’s (WHO) definition for an ADR
is used; that is, “any response to a drug which is noxious,
unintended, and which occurs at doses normally used in
man for prophylaxis, diagnosis or therapy of disease, or for
the modification of physiological function” (Uppsala
Monitoring Center, WHO Collaborating Centre for
International Drug Monitoring 2000). An adverse drug event
(ADE) is any undesirable experience associated with the
use of a medical product in a patient (Nebeker et al 2004).
This broad definition includes ADRs and other events
(including medication errors) related to the prescribing,
preparation, dispensing, or administration of medications.
In broad terms, an ADR is an adverse event with a causal
link to a drug. Both ADRs and ADEs have been targeted to
improve patient safety.
Epidemiological studies have suggested that ADRs
account for about 5% of all hospital admissions (Einarson
1993; Lazarou et al 1998; Roughead et al 1998), although
estimates of up to 28% of drug-related admissions have been
suggested (Miller 1974; Jick 1994). Also, the risk of ADRs
increases when a patient is hospitalized. Lazarou and
colleagues (1998) conducted a meta-analysis of 39
prospective studies from US hospitals to determine the
incidence of ADRs in hospitalized patients. Although the
results have been criticized (Bates 1998; Kvasz et al 2000),
the authors reported that ADRs may be the fourth to sixth
leading cause of death in hospitalized patients, with fatal
ADRs occurring in 0.32% of the cases.
The significant impact that ADEs and ADRs have on
morbidity, mortality, and costs cannot be overemphasized,
nor should it be ignored. ADRs have been reported to be
associated with a greater length of hospital stay, which
consequently increases healthcare costs. McDonnell and
Jacobs (2002) assessed the potential preventability of ADRs
directly related to a patient’s hospital admission. They
considered that 62.3% of these were potentially preventable.
The findings of the IOM report (Kohn et al 1999) estimate
the total US costs, including lost income, lost household
production, disability, and healthcare costs, due to
preventable ADEs at US$17 billion to US$29 billion.
As many ADRs often go unrecognized or unreported,
an organized ADR monitoring program is one mechanism
to more actively detect ADRs, and consequently positively
affect the quality of patient care.
Clinical importance of ADR
monitoring and reporting
During clinical trials, medicines are generally studied in a
controlled environment, for a relatively small number of
patients, and usually for a limited duration. While the
approval process includes extensive safety testing, these
trials sometimes exclude the elderly, the very young, and
patients with comorbidities. Often patients on multiple drug
therapy and patients with decreased renal and hepatic
function are excluded. For these patient populations, any
vulnerability to ADRs may be missed. Furthermore, it is
extremely difficult to predict how practitioners will actually
use medications in practice.
Once the drug is commercially available, the exclusion
criteria applied in clinical trials no longer exist. Thus,
exposure to the drug will last longer, as therapy may continue
long term, increasing the possibility of previously undetected
problems to arise and be identified. Additionally, adverse
reactions may occur at such a low frequency that they are
not being detected in the small numbers of patients included
in clinical trials; consequently, widespread use of medicines
in the general population can increase the chances for
uncovering reactions not previously reported for a particular
drug during the marketing approval process.
Post-marketing surveillance, also known as pharmaco-
vigilance, is the process of identifying, reporting, and
responding to risk-benefit issues arising with marketed
medicines. Post-marketing surveillance programs use the
information generated from these reports to update drug
labeling and, on occasions, to reevaluate the approval or
marketing decision. Even if the report does not warrant
labeling changes, the information provided can signal
potential problems with the use of certain drugs for which
recommendations can be provided to decrease the risk, or
be further investigated. Once the reports are studied and
evaluated, the data generated can help to estimate risk
patterns, such as identifying populations at risk of
developing an ADR with certain medications, investigate
the preventability of these ADRs to provide indicators for
quality improvement, or signpost for interventions. The
dissemination of this information is also a crucial aspect of
pharmacovigilance, as it is needed for drug prescribing and
regulation (Brewer and Colditz 1999).
In summary, post-marketing surveillance programs are
essential in every country for monitoring the occurrence of
ADRs, as the data derived from within the country may
encourage national regulatory decision making. Thus, theseTherapeutics and Clinical Risk Management 2005:1(3) 183
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programs may contribute to decreased morbidity, mortality,
length-of-stay, healthcare costs, and liability associated with
ADRs.
The New Zealand perspective
The New Zealand Quality of Healthcare Study (NZQHS)
(Davis et al 2002, 2003) examined 6579 medical records
using two-stage retrospective review applied to a
representative sample of hospital admissions for the calendar
year of 1998. The sample was drawn by systematic list
selection, after the exclusion of specialist institutions, from
13 public hospitals providing acute care and with more than
100 beds. The main aim was to quantify the impact of
adverse outcomes of healthcare management in the New
Zealand public hospital system.
The NZQHS reported that 12.9% of public hospital
admissions were associated with an adverse event, a rate
that is similar to those recorded for Australia (16.6%) and
the United Kingdom (10.8%) in comparable studies (Wilson
et al 1995; Vincent et al 2001). Half of the events in this
New Zealand study were shown to be preventable and
occurred inside hospital, and, of these, 7.5% were associated
with pharmacological treatment and 10.7% with therapy-
related incidents (Davis et al 2002, 2003).
The Centre for Adverse Reactions Monitoring (CARM)
in Dunedin is New Zealand’s national monitoring centre
for adverse reactions (New Zealand Pharmacovigilance
Centre 2004). It collects and evaluates spontaneous reports
of adverse reactions to medicines, vaccines, herbal products,
and dietary supplements from health professionals in New
Zealand. Currently, the CARM database holds more than
48 000 reports, providing New Zealand-specific information
on ADRs to these products and serving to support clinical
decision making when unusual symptoms are thought to be
therapy related. CARM collaborates with and pools
anonymized data with other national monitoring centers into
the database of the WHO’s International Drug Monitoring
Programme.
CARM reports its findings to a government-appointed
committee, the Medicines Adverse Reaction Committee
(MARC). This committee makes recommendations to
Medsafe (NZ Medicines and Medical Devices Safety
Authority), which is a business unit of the Ministry of Health
and is the authority responsible for the regulation of
therapeutic products in New Zealand (New Zealand
Medicines and Medical Devices Safety Authority 2004).
Medsafe has the responsibility for implementing strategies
that should result in the safer use of medicines. MARC meets
four times a year to review published material, all fatal
reports, and selected reports of significant, unusual, or
serious reactions reported to CARM.
In addition to CARM, the Intensive Medicines
Monitoring Programme (IMMP) monitors more closely
selected new medicines using a method called prescription
event monitoring, supplementing New Zealand’s ADRs
database. The IMMP aims at measuring the incidence of
adverse reactions, their characterization, early identification
of previously unrecognized reactions, and the construction
of a risk profile for each new medicine. This network is
able to keep New Zealand’s international reputation in ADR
monitoring and reporting abreast of the latest concerns
around drug safety; for example, New Zealand led the world
in taking regulatory action over agranulocytosis due to
mianserin and liver toxicity due to nefazodone (Coulter and
Edwards 1990; WHO 2003). All these programs constitute
a significant contribution of New Zealand to the international
ADR database and towards the improvement of safety of
medicines worldwide.
The role of the pharmacist
Pharmacists have a central role in drug safety by contributing
to the prevention, identification, documentation, and
reporting of ADRs. All healthcare providers have roles to
play in maintaining a balance between a medicine’s benefits
and risks. Once a drug is available to the public, making a
determination about its safety is the shared responsibility
of all who are part of the prescribing process, including
patients. Pharmacists clearly understand that no drug product
is completely safe and that pre-marketing trials do not fully
identify the risks, particularly of recently marketed drugs.
As part of the healthcare team, pharmacists advise on drug
use or on the introduction to or withdrawal of a drug from
the market and are often called upon in establishing the
likelihood that an adverse event is in fact an ADR.
National drug monitoring programs throughout the
world differ in their sources of participation in the reporting
of ADRs by healthcare professionals. In contrast to Canada
or the US, where the majority of the reports come from
pharmacists, some countries, such as France, Ireland,
Malaysia, New Zealand, the Nordic countries, and the UK,
have the largest contribution of ADR reports coming from
physicians (The Learning Centre 1999). The reasons for low
reporting rates by pharmacists in these countries have not
been adequately analyzed. It has been suggested that it mayTherapeutics and Clinical Risk Management 2005:1(3) 184
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result from the simple fact that pharmacists are excluded
from reporting ADRs to the national reporting program,
which is the situation in the Nordic countries (eg, Finland
and Sweden) (van Grootheest et al 2004). A study in the
UK concluded that hospital pharmacists require continuing
stimulation and education about reporting in order to raise
further the profile of their role in reporting of suspected
ADRs to their national pharmacovigilance program (Davis
et al 1999).
Even among countries where pharmacists are allowed
to report ADRs to their national program, lower reporting
rates by pharmacists are observed. New Zealand is a good
example of this case. As shown in Figure 1, between January
and June 2004, only 5.7% of CARM reports were submitted
by pharmacists (personal communication, CARM, 18 Mar
2005) compared with about 70% of ADR reports submitted
to the MEDWATCH program in the US by pharmacists, most
of which are from hospital-based pharmacy practitioners.
Canada shows similar trends to the US in ADR reporting;
for example, in the fiscal year of 1998–1999, at the British
Columbia Regional ADR Centre, most ADR reports were
generated by pharmacists (38.8% and 34.8% by hospital
and community pharmacists, respectively), physicians’
reports accounting for only 10.8% (The Learning Centre
1999).
Predisposing factors for
underreporting
Underreporting of ADRs is a common phenomenon in
spontaneous post-marketing surveillance programs.
Underreporting may delay signal detection and cause
underestimation of the size of a problem. Correcting for
underreporting is difficult, because its extent is unknown
and variable. Having a better understanding of the
predisposing factors, particularly as they relate to the
pharmacy profession, can assist pharmacy practitioners in
establishing ways to decrease underreporting.
Barriers to improved monitoring and reporting of ADRs
have been analyzed in various studies
 (Sweis and Wong
2000; Green et al 2001; van Grootheest et al 2002; Kelly et
al 2004) and can be summarized as:
￿ fear of personal and organizational liability
￿ lack of resources for surveillance and reporting
￿ labor-intensive, complex, and time-consuming reporting
processes
￿ ambiguity in interpreting whether the medication was
the cause of the adverse event
￿ minimal feedback provided to reporters
￿ no incentives, rewards, or motivation to report
￿ lack of knowledge and confidence to distinguish between
significant ADRs and minor ones
￿ surveillance and reporting functions without a leader.
The Australian report by Kelly and colleagues (2004) looked
more closely into the factors influencing ADR reporting in
hospitals and classified them into predisposing and disabling
factors (Table 1). Through a questionnaire to all health
professionals involved in the ADR reporting process, it was
found that knowledge appeared to be a greater influence on
ADR reporting than attitudes and beliefs, particularly among
doctors. Interestingly, pharmacists indicated a high level of
knowledge and were identified and utilized by other
healthcare professionals as key facilitators of the reporting
process.
Factors influencing the underreporting by pharmacists
specifically have also been investigated by some authors.
Sweis and Wong (2000) conducted a survey of UK hospital
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Figure 1 Sources of adverse drug reaction (ADR) reports in New Zealand,
January–June 2004. Abbreviations: GPs, general practitioners; HCPs, healthcare
professionals; Rx, pharmacists.
Table 1 Factors influencing adverse drug reaction (ADR)
underreporting
Predisposing factors
Knowledge
Unsure how to report an ADR
Unsure who is responsible for reporting ADRs
Unsure which drug was responsible for the ADR
Unsure if the reaction was a side effect rather than an ADR
Attitudes and beliefs
Believed only safe drugs are allowed on the market
Concerned about confidentiality of information
Reporting could show ignorance
Concerned about legal liability by reporting
Difficult to admit harm to patient
Willing to publish or report only unusual cases in the literature
Disabling factors
Too busy to send ADR reports
Form unavailable when needed
Insufficient data to complete a report
Source: Adapted from Kelly et al (2004).Therapeutics and Clinical Risk Management 2005:1(3) 185
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pharmacists which showed that they were more likely to
report serious and rare ADRs and those associated with
newly marketed drugs (predisposing factor: attitudes or
beliefs). Van Grootheest and colleagues (2002) surveyed
community pharmacists in The Netherlands, showing that
the most frequently mentioned barriers to reporting were
the ADR assumed to be already known or uncertainty about
the causal relationship between the ADR and a drug
(predisposing factor: knowledge) and the reporting
procedure being too time-consuming (disabling factor:
time).
Factors influencing the underreporting by New Zealand
pharmacists have not yet been investigated or reported, but
would be useful for establishing corrective actions.
Policy and procedures for ADR
reporting in hospitals
Although CARM produces the highest rate of reporting
ADRs in the world, both in terms of reports per 1000 doctors
and reports per million population (New Zealand
Pharmacovigilance Centre 2004), having national programs
as the only source of information on ADR trends does not
allow individual healthcare organizations, such as hospitals,
to analyze the contribution of drug-induced illness to the
morbidity, mortality, length of stay of patients, and the
overall healthcare costs of the individual organization. As
mentioned previously, it is well known that there is
significant underreporting not only for ADRs, but for all
ADEs. Most hospitals in New Zealand rely on spontaneous
reporting of ADRs by their staff directly to CARM (personal
communication, CARM, 18 Mar 2005), without any type
of analysis of the report prior to its submission. As shown
in Figure 1, ADR reports submitted by hospitals represent
only about 10% of the total reports received by CARM.
Similar types of reporting systems in other parts of the world
have been shown to detect only a small percentage of ADRs
that occur in hospitals (Cullen et al 1995).
Given the perceived failure of spontaneous reporting
systems and the paucity of ADR reports, hospital
accreditation commissions in countries such as Canada or
the US recommended the institution of more active methods
of ADR detection to supplement spontaneous reports in
hospitals. In these countries, it is usually the department of
pharmacy staff who coordinate the hospital’s ADR reporting
program and, in most cases, do so under the direction of the
institution’s pharmacy and therapeutics (P&T) committee.
All ADR reports received are initially screened (and
occasionally analyzed for causality or severity) by
pharmacists before being presented to the P&T committee
for review and further action. The American Society of
Health-System Pharmacists (ASHP) has developed a very
useful guideline for ADR monitoring and reporting by
pharmacists in organized healthcare systems, which
summarizes not only the role of the pharmacist, but also the
crucial components of a comprehensive ADR reporting
program in hospitals (ASHP 1995).
Taking the above into consideration, it appears to be
important for hospitals to establish their individual policies
and procedures for ADR reporting to supplement a country’s
spontaneous reporting system. In an attempt to have an initial
understanding of this issue in New Zealand, we informally
(via email communication with hospital pharmacists)
investigated if District Health Boards (DHBs) had individual
policies for ADR reporting, and whether these policies
covered the components of a comprehensive in-house ADR
reporting program as outlined by the ASHP guidelines. No
source other than the written policies was utilized for the
latter review.
Of the 22 DHBs to which we put the simple question
“Do you have in-house policies or procedures for reporting
ADRs within your DHB to supplement reporting to
CARM?”, 14 responded. Eight DHBs had specific ADR
reporting policies in place, three were working on writing
one, and three did not have a formal policy in place, though
their pharmacy departments did issue advice on reporting
directly to CARM. Table 2 provides the results of how many
DHBs included the specific components of an “ideal” in-
house ADR program in their policy.
The results summarized in Table 2 show that for the eight
hospitals that indicated having ADR policies and procedures
available, generally these can be considered adequate in
ensuring that if an ADR occurs, a multidisciplinary team
(including the pharmacist) is involved in the reporting
procedure, and that the message is documented and
conveyed properly to minimize the risk of re-occurrence.
However, the policies at these hospitals may be inadequate
for providing useful guidance in assessing individual ADRs,
as they lack provisions for detecting, classifying,
determining causality, assigning probability, or managing
ADRs, all essential for an ideal in-house ADR reporting
program.
Although generalizations cannot be made from this
informal investigation, the review of the policies from the
eight DHBs that responded to having established policies
for reporting ADRs suggests that important features of an
in-house ADR reporting program within hospitals are beingTherapeutics and Clinical Risk Management 2005:1(3) 186
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omitted, and that a more profound investigation into the
subject may be warranted to help clarify the New Zealand
perspective. More comprehensive guidelines on ADR
monitoring and reporting by pharmacists than those
provided in the Pharmacy Practice Handbook
(Pharmaceutical Society of New Zealand 2004) may also
assist pharmacists in New Zealand to become more actively
involved and exert leadership in the development,
maintenance, and ongoing evaluation of ADR programs
within their practice settings.
Improving ADR reporting
The reporting of ADRs needs continuous stimulation. It is
important to achieve the development of a positive attitude
towards pharmacovigilance among healthcare professionals,
including pharmacists, so that ADR reporting becomes an
accepted and understood routine. Research into pharmacist
ADR reporting has shown that those who undergo training
are more likely to report (Sweis and Wong 2000; Green et
al 2001) and that continued educational initiatives
 are needed
for the multidisciplinary team to sustain a successful ADR
monitoring and reporting program (Kelly et al 2004).
Considering that the ADR reporting rates by New
Zealand pharmacists are significantly lower than those of
physicians, as well as significantly lower than those
contributed by pharmacists in other countries, the following
recommendations have been suggested to stimulate
pharmacists to overcome some of the potential barriers to
ADR reporting, improve their ADR detection skills, and
participate more actively in ADR prevention and
management strategies; all of these may help them not only
to achieve better ADR reporting rates, but to improve the
quality and safety of medication use by their patients.
Making ADR reporting forms accessible
ADR reporting forms should be carried by clinical
pharmacists during their routine ward rounds, as well as
being readily available in all the wards for other members
of the multidisciplinary team to use them (ASHP 1995;
Uppsala Monitoring Center 2000). If no hospital-based
reporting forms are available, use the ones provided by
CARM. Alternatively, an in-house version can be developed.
This alternative provides the opportunity to make the form
more user-friendly, whereby only the first part of the
reporting form is required to be completed by the reporting
person; the rest can then be completed by the clinical
pharmacist or other member of the team who can assess the
reaction in more depth.
Assuring that the ADR program is
multidisciplinary
A collaborative multidisciplinary approach to ADR
monitoring and reporting is essential for a successful
program (ASHP 1995; Uppsala Monitoring Center 2000).
Nursing is a critical component of the ADR process because
nurses spend the most time with the patients, and physician
knowledge and experience is essential in the assessment and
evaluation of an ADR. By assigning a clinical pharmacist
to the wards, the detection and assessment of ADRs can be
greatly enhanced, as many ADRs are discussed on rounds
but rarely documented. Also, establishing contacts with the
Table 2 Features of adverse drug reaction (ADR) reporting
policies in some New Zealand District Health Boards (DHBs)
Components for an ideal in-house
ADR program (ASHP 1995) Nr of DHBs
Provides a definition of an ADR 2
Classifies ADRs according to type 1
Uses detection identifiers (ie, triggers that signal an 2
investigation is warranted for ADR), such as emergency
box usage, use of medicine to treat a symptom rather
than a disease (eg, antihistamines)
Provides management guidance for ADRs 3
Evaluates all ADRs individually (ie, all reports of suspected 3
ADRs are reviewed and differentiated from obvious
medication errors)
Includes probability assessment (ie, by the use of scales or 0
algorithms to determine the likelihood that the event is
medicine related)
Provides severity ranking for all ADRs 0
Addresses the multidisciplinary responsibility for reporting 6
Uses in-house reporting forms (other than or in addition 7
to those of CARM)
Tracks the pattern and incidence of ADRs within the DHB, 0
which are reviewed by relevant committees (eg, P&T), for
action and feedback
Recommends pharmacist’s involvement in the ADR 5
reporting procedure
Has provisions for follow-up reporting of all reported ADRs 6
(eg, documentation in medical notes, patient informed,
medic alert bracelet etc)
Has provisions to notify the patient’s general practitioner 5
about the ADR
Has provisions for further notification to CARM 5
Abbreviations: CARM, Centre for Adverse Reactions Monitoring; P&T,
pharmacy and therapeutics.Therapeutics and Clinical Risk Management 2005:1(3) 187
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medical records and emergency departments may add
significant value to the ADR detection process. Asking
members of these departments to contact the pharmacy when
they suspect an ADR is likely to contribute to a broader
multidisciplinary ADR program. The hospital laboratory can
provide assistance in the detection of ADRs by reporting
patients with elevated levels of certain medications or in
the detection of antibiotic-associated diarrhea with a report
of positive Clostridium difficile toxin assays (Vitillo 2000).
Centralizing ADR reporting activities
Completed CARM reports, or the equivalent in-house ADR
form, should initially be forwarded to a central area, such
as the Medicines Information Center (MIC), for further
assessment (Michel and Knodel 1986; ASHP 1995; Andrew
et al 2001). A fax line, email, and online ADR reporting
forms can also be available to facilitate communication in
alerting the multidisciplinary team to an ADR (Vitillo 2000).
Once in the central area, ADR reports must be followed up
by a pharmacist. Thus, pharmacovigilance must be integrated
in the activities of dispensing, MIC, and ward pharmacists.
Targeting antidote medication
This is a widely used method to improve detection of ADRs
(Classen et al 1991; Dormann et al 2000). Pharmacists screen
orders, usually assisted by a computerized alerting system,
for antidote medications, discontinuation orders, dosage
decreases, and laboratory test orders to detect ADRs. Reports
of toxic plasma concentrations of medications with low
therapeutic indexes are also used.
Talking to patients
Pharmacists play an integral role in gathering information
from their patients, as well as in educating patients on various
aspects of medication use, including safety (ASHP 1995).
Many patients are not aware of important risk information
about their medications, so they would not know what to
expect if they experienced a potentially harmful reaction
caused by one of their medications.
Providing feedback
ADR report information should be disseminated to the
reporters and to all the healthcare professional staff members
(ASHP 1995) in the form of newsletters (Vitillo 2000), such
as an “ADR Bulletin”, which should be available on a regular
basis for educational purposes and should reflect local efforts
in the monitoring, prevention, detection, and management
of ADRs.
Seeking administrative support
Submitting a summary of all the ADR reports to the P&T
(ASHP 1995; Vitillo 2000) or other equivalent hospital
medicines committee before forwarding them to CARM
may prove to be valuable. These reports can be sent under
the hospital medicines committee’s name; thus the names
of individual healthcare professionals and patients can be
kept confidential. Collaborative efforts with national and
international institutions working in pharmacovigilance can
prove to be extremely valuable and can provide useful
resources for ADR monitoring programs.
Providing incentives for ADR reporting
Examples include issuing certificates or recognition awards
or pens with reminding logos on ADR reporting, which have
been used as incentives to motivate departments other than
pharmacy to report ADRs (Vitillo 2000).
Conclusions
The effectiveness of an ADR monitoring and reporting
program depends on the awareness of all healthcare
providers. It is important to address within the pharmacy
profession that ADR surveillance is a priority and a
professional responsibility. It is essential that programs
aimed at increasing ADR surveillance include processes that
are user friendly and lack negative associations or stigma.
More studies on ADR monitoring and reporting in New
Zealand are necessary.
ADR awareness programs have been developed in
various institutions to increase the detection of ADRs,
implement strategies for successful prevention and
management of ADRs, and consequently contribute to
improving the safety of medication use. International ADR
programs indicate that a multidisciplinary approach and the
involvement of the P&T or other equivalent hospital
medicines committee are essential to assure more effective
education and communication among all healthcare
professionals on the clinical importance of ADR
surveillance. Lastly, it is also important to assure that the
awareness programs are ongoing, to avoid ADR surveillance
losing “momentum”. Several strategies for promoting
successful, ongoing ADR programs have been provided in
this review.Therapeutics and Clinical Risk Management 2005:1(3) 188
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